Corcept Therapeutics Inc (Corcept) discovers and develops pharmaceutical products for the treatment of endocrine, metabolic, oncologic and neuropsychiatric disorder. The company focuses on disorders associated with steroid hormone called cortisol. The company operates through a single reportable segment, namely, the discovery, development and commercialization of pharmaceutical products. Corcept’s marketed products include Korlym (mifepristone), a cortisol receptor blocker indicated for the control of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Corcept focuses on research and development (R&D) operations to expand its commercial product portfolio and for the development of its pipeline products. It covers obesity, non-small cell lung cancer, anxiety, diabetes, Alzheimer’s disease, hypertension and neurodegenerative diseases. In FY2023, the company spent US$184.4 million on its R&D. The company seeks patent protection for its innovative developments and formulations. It developed a strong portfolio of intellectual property covering all its major developments, their formulations and implications. The company has ten US compositions of matter patents containing claims related to three structurally distinct series of next-generation cortisol modulators. Five of these patents were issued in Europe. The expiry dates of these US and European patents range from 2025 to 2039.